SAFETY OF LEMBOREXANT IN ELDERLY SUBJECTS WITH INSOMNIA: RESULTS FROM A PHASE 3 STUDY (SUNRISE 1)

被引：1
|
作者：
Rosenberg, Russell [1 ]
Filippov, Gleb [2 ]
LoPresti, Antonia [2 ]
Kumar, Dinesh [2 ]
Murphy, Patricia [2 ]
Moline, Margaret [2 ]
机构：
[1] NeuroTrials Res Inc, Atlanta, GA USA
[2] Eisai Inc, Tokyo, Japan
来源：
AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY | 2019年 / 27卷 / 03期
关键词：
D O I：
10.1016/j.jagp.2019.01.109
中图分类号：
R592 [老年病学]; C [社会科学总论];
学科分类号：
03 ; 0303 ; 100203 ;
摘要：
NR - 21
引用
收藏
页码：S155 / S156
页数：2
相关论文
共 50 条
  • [21] Efficacy and safety of lemborexant in adults with insomnia: comparing Japanese and non-Japanese subgroups from the global, phase 3, randomized, double-blind, placebo-controlled SUNRISE 2 study
    Inoue, Yuichi
    Watanabe, Takeshi
    Takashima, Shuya
    Takase, Takao
    Ishikawa, Kohei
    Kubota, Naoki
    Yardley, Jane
    Moline, Margaret
    JOURNAL OF CLINICAL SLEEP MEDICINE, 2021, 17 (05): : 1067 - 1074
  • [22] EFFECTIVENESS AND SAFETY OF LEMBOREXANT IN SUBJECTS PREVIOUSLY TREATED WITH PLACEBO FOR 6 MONTHS IN SUNRISE-2
    Yardley, J.
    Inoue, Y.
    Pinner, K.
    Perdomo, C.
    Filippov, G.
    Kubota, N.
    Moline, M.
    SLEEP, 2020, 43 : A181 - A182
  • [23] Efficacy and safety of lemborexant in subjects previously treated with placebo for 6 months in a randomized phase 3 study
    Yardley, Jane
    Inoue, Yuichi
    Pinner, Kate
    Perdomo, Carlos
    Kubota, Naoki
    Perlis, Michael L.
    Moline, Margaret
    SLEEP MEDICINE, 2023, 110 : 111 - 119
  • [24] THE INCIDENCE OF ABNORMAL DREAMS AND NIGHTMARES IN ADULTS WITH INSOMNIA TREATED WITH LEMBOREXANT: RESULTS FROM TWO PHASE 3 STUDIES
    Roth, T.
    Yardley, J.
    Pinner, K.
    Kumar, D.
    Cheng, J. Y.
    Moline, M.
    SLEEP MEDICINE, 2022, 100 : S142 - S142
  • [25] THE IMPACT OF LEMBOREXANT TREATMENT ON INSOMNIA DISEASE SEVERITY: RESULTS FROM A POOLED ANALYSIS OF TWO PHASE 3 STUDIES
    Roth, T.
    Rosenberg, R.
    Yardley, J.
    Kumar, D.
    Pinner, K.
    Perdomo, C.
    Moline, M.
    SLEEP MEDICINE, 2019, 64 : S325 - S326
  • [26] Efficacy and safety of lemborexant in subjects with insomnia disorder receiving medications for depression or anxiety symptoms
    Krystal, Andrew
    Blier, Pierre
    Culpepper, Larry
    Nierenberg, Andrew A.
    Takaesu, Yoshikazu
    Kubota, Naoki
    Moline, Margaret
    Malhotra, Manoj
    Pinner, Kate
    Yardley, Jane
    NEUROPSYCHOPHARMACOLOGY REPORTS, 2025, 45 (01)
  • [27] AN OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TREATMENT WITH LEMBOREXANT IN SUBJECTS WITH CHRONIC INSOMNIA (SOMNUS STUDY)
    Ozone, Motohiro
    Hirota, Susumu
    Ariyoshi, Yu
    Hayashida, Kenichi
    Ikegami, Azusa
    Habukawa, Mitsunari
    Ohshima, Hayato
    Harada, Daisuke
    Hiejima, Hiroshi
    Kotorii, Nozomu
    Murotani, Kenta
    Taninaga, Takehiro
    Uchimura, Naohisa
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2025, 28 : i242 - i243
  • [28] A MULTICENTER, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LEMBOREXANT ALTERNATIVE THERAPY IN SUBJECTS WITH INSOMNIA (SOMNUS STUDY)
    Ozone, M.
    Hirota, S.
    Ariyoshi, Y.
    Hayashida, K.
    Ikegami, A.
    Habukawa, M.
    Ohshima, H.
    Harada, D.
    Hiejima, H.
    Kotoril, N.
    Murotani, K.
    Taninaga, T.
    Uchimura, N.
    SLEEP MEDICINE, 2024, 115 : 159 - 159
  • [29] CHARACTERISTICS OF INSOMNIA SUBJECTS SCREENED FOR TRANSITIONING FROM ZOLPIDEM TARTRATE TO LEMBOREXANT IN A MULTICENTER PILOT STUDY
    Ahmad, M.
    Malhotra, M.
    Amchin, J.
    Kumar, D.
    Perdomo, C.
    Moline, M.
    SLEEP, 2020, 43 : A183 - A183
  • [30] LONG-TERM EFFECT OF LEMBOREXANT ON FATIGUE IN SUBJECTS WITH INSOMNIA DISORDER: PATIENT-REPORTED OUTCOME FROM THE 6-MONTH PLACEBO-CONTROLLED TREATMENT PERIOD OF THE PHASE 3 STUDY SUNRISE-2
    Yardley, J.
    Moline, M.
    Pinner, K.
    Perdomo, C.
    Fillipov, G.
    Karppa, M.
    SLEEP MEDICINE, 2019, 64 : S264 - S264
12345